RxDoctor Payments Data

Timothy Larson, MD

Cardiovascular Disease · Tacoma, WANPI 1679782676

Payments from drug & device makers

$4,415in general payments, 2019–2025

Across 34 payments — averaging $129.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Beone Medicines USA, Inc.$2K
  • Abbott$1K
  • Abiomed$530
  • Boston Scientific$225
  • Medtronic$92
  • Edwards Lifesciences$90
  • plus $345 from 9 others

What the payments were for

  • Consulting fees$3,00068%
  • Food & beverage$1,41532%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,415 in reported general payments places this provider in the 75th percentile of 370 cardiovascular disease providers in Washington.

See all cardiovascular disease providers in Washington

Medicare billing

Part B allowed, 2024
$171,864
Medicare patients
1,734
Services billed
2,712

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban279$343,620
EntrestoSacubitril/Valsartan100$117,936
JardianceEmpagliflozin98$107,489
XareltoRivaroxaban52$76,655
BrilintaTicagrelor29$15,724
Metoprolol Succinate290$3,588
Atorvastatin Calcium227$2,700
Ranolazine ErRanolazine24$2,366
Digoxin61$1,993
Rosuvastatin Calcium87$1,862
Losartan Potassium139$1,740
ClopidogrelClopidogrel Bisulfate79$1,546
Carvedilol149$1,528
Diltiazem 12hr ErDiltiazem Hcl11$1,513
Potassium Chloride57$1,252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$20$117,936100 claims
Boehringer IngelheimJardiance$83$107,48998 claims
Johnson & JohnsonXarelto$76$76,65552 claims
AstraZenecaBrilinta$42$15,72429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 370 cardiovascular disease providers in Washington.

Other cardiovascular disease in Tacoma

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →